Shenzhen VMAX New Energy (688612.SH) plans to launch a restricted stock incentive plan in 2026.
Weimars (688612.SH) disclosed the draft of the 2026 restricted stock incentive plan, which proposes to grant 2.3168 million restricted stocks, accounting for 0.5527% of the company's total share capital at the time of the announcement of the incentive plan draft, to be granted in one lump sum with no reserved rights. Among these, the number of first-category restricted stocks to be granted is 1.7471 million shares, and the number of second-category restricted stocks to be granted is 569,700 shares. A total of 86 individuals are proposed as the incentive recipients. The grant price for both the first-category and second-category restricted stocks is set at 19.45 yuan per share.
Shenzhen VMAX New Energy (688612.SH) has disclosed the draft of its 2026 restricted stock incentive plan. The number of restricted shares proposed for this incentive plan is 2.3168 million shares, accounting for 0.5527% of the total share capital of the company at the time of the announcement of the draft incentive plan, with a one-time grant and no reserved rights. Among this, the number of first-class restricted shares proposed to be granted is 1.7471 million shares, and the number of second-class restricted shares proposed to be granted is 569,700 shares. A total of 86 individuals are proposed to be granted the incentive. The grant price for both the first-class and second-class restricted shares is 19.45 yuan per share.
Related Articles
TIMES CHINA (01233) reported a cumulative contract sales amount of approximately 2.237 billion yuan in the first eight months, a year-on-year decrease of 38.41%.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-1179 Injection has obtained the Clinical Trial Approval Notification.
Nanchang Jiahui, a shareholder of Jiangxi Guoke Defence Group (688543.SH), intends to reduce its holdings by no more than 3%.
TIMES CHINA (01233) reported a cumulative contract sales amount of approximately 2.237 billion yuan in the first eight months, a year-on-year decrease of 38.41%.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-1179 Injection has obtained the Clinical Trial Approval Notification.
Nanchang Jiahui, a shareholder of Jiangxi Guoke Defence Group (688543.SH), intends to reduce its holdings by no more than 3%.
RECOMMEND
